Ocuphire Pharma, Inc. Profile Avatar - Palmy Investing

Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily prese…

Biotechnology
US, Farmington Hills [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Ocuphire Pharma, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of OCUP's Analysis
CIK: 1228627 CUSIP: 67577R102 LEI: - UEI: -
Secondary Listings
OCUP has no secondary listings inside our databases.